Selinexor receives Conditional Marketing Authorisation in Europe for the treatment of relapsed and or refractory myeloma patientsAccess, MyelomaMarch 30, 2021
The FDA approves melphalan flufenamide for patients with relapsed or refractory myelomaAccess, MyelomaMarch 1, 2021
MPE webinar on ASH 2020 myeloma and AL amyloidosis highlightsAL amyloidosis, MPE, MyelomaDecember 8, 2020
ASH 2020 | Certain people with blood cancers and COVID-19 infection vulnerable to severe illnessAL amyloidosis, Conferences, MyelomaDecember 6, 2020
ASH 2020 | The phase III trial Apollo supports administering daratumumab subcutaneously instead of intravenously in relapsed or refractory myeloma patientsConferences, MyelomaDecember 5, 2020
